Enzon Sells Interest in Schering Drug

Enzon Pharmaceuticals Inc. said Monday it sold a 25 percent share in Schering-Plough’s hepatitis C drug Peg-Intron to privately held Drug Royalty Corp. for $92.5 million.
Hemscott